test
Just having some fun after a great ski trip to Breckenridge, Co for a couple of weeks. Let's get back into it.
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products include IFX-1 and IFX-2. The company was founded by Niels...
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that,...
test
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products include IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
IFRX: InflaRx N.V.
2021-10-27 07:30:00
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
Keeping this one on watch most likely looking for the same volume coming in Monday. We closed very strong on Friday Which typically means we are looking for a strong move to the upside on Monday... Also looking for that SweetSpot break at $2.85 for Entry Confirmation.
Pupm&Dump trading strategy idea.
$IFRX is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $3,21;
stop-loss — $3,35;
take-profit — $2,93/MOC
Do not view this idea as a recommendation for trading or investing. It is...
InflaRx NV is a clinical-stage biopharmaceutical company that is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating...
Trade Safe! Don`t be greedy!
Take care and place small trades! If necessary, I will place more long trades at this asset!
In my opinion, this stock is at a good opportunity and has good potential for the stock price to go up!
Contextual immersion trading strategy idea.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the United States and Europe.
The share price rose after good earnings. I see some preconditions the share price will continue growing.
The demand for shares of the company still looks higher...
IFRX: InflaRx N.V.
2020-02-26 07:30:10
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
IFRX has just touched a semi-stable horizontal support and may bounce up or perhaps dip down to the underlying support and then rebound. Keep a close eye on this one.
>Bio of InflaRX<
2008 - Dutch pharma company founded in Germany
2017 - IPO on NASDAQ with gross proceeds of +$100M
2018 - Second round of funding with +$100M
2019 - Balance sheet shows working capital > $150M
>My opinion<
Seems like this company has recently hit a rough patch as far as their scientific studies go, but the financials look rock solid.
I don't...
This is my first share post. Using this as a swing trade analysis.
1. Stock broke the 50 day MA on May 7th, closing at $42.68
2. Stock Reached 20 RSI on May 20th, closing at $38.41 making a 1st Low of $38.18 with 20 RSI.
3. Stock made a 2nd new low on May 22nd of $37.87, closing at $38.05 with RSI reversing upwards to 30 RSI.
4. Market shows sign of reversal...
After a blah 2018, trading sideways to downward for most of that year, IFRX had a final, sharp captulation move down in December 2018 and then after the last set of sellers threw in the towel, a sharp rally up. From there...2019, we have been in an uptrend. I like the sharp, drastic moves higher and lower...with higher highs and higher lows. With the most...
Wow, this stock has some nice, sharp moves up and down within a nice uptrend that started in 2019. Looks overbought right now, depending on timing...might be a nice swing trade between 43.50 and 41.50. Adding this to my watchlist. Will tweet if/when I enter along with stop loss and profit targets
